Crown Equity Holdings, Inc. (CRWE)
Crown Equity Holdings Inc., together with its digital network of Websites, offers media advertising, branding and marketing services as a worldwide online multi-media publisher. The company focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Its advertising services cover and connect a range of marketing specialties, as well as providing search engine optimization for clients interested in online media awareness.
Crown Equity Holdings Inc. (CRWE.OB) announced that it has launched CRWE Tube, www.crwetube.com, a video sharing site that allows billions of people around the world to upload watch and share original videos.
“The CRWE Tube team has built an exciting media platform, which allows people and businesses large and small to quickly and efficiently reach a vast new audience,” said Kenneth Bosket, President of Crown Equity Holdings Inc. “With online videos continuing to experience explosive, viral growth and the web rapidly moving from text to video, businesses will need to adapt to the shift in video distribution technology or quickly become irrelevant to their consumers who anticipate seeing video everywhere online.”
The top benefits of video marketing are attracting a large audience, engages the senses, access at any time and achieving top rankings in the search engines. Video enables you to capture people who like to watch rather than read. This extends the reach of your content because you can appeal to visual learners. If a picture is worth a 1000 words, then video does even more because you can create live movies with sound. This engages more senses than written text which only uses one medium. You can view videos with all kinds of devices these days eg ipods, cell phones, laptops, etc. allowing you to access video content anywhere at any time. Google recently introduced Universal Search. This means videos now appear in the search results pages. For example if you Google “Mustang” you’ll see video listings of mustang cars on the first page of Google.
For more information please visit official website of CRWE: www.crownequityholdings.com
BSD Medical Corporation (NASDAQ:BSDM) a leading provider of medical systems that treat cancer and benign diseases using heat therapy, reported financial results for its first fiscal quarter ended November 30, 2011, including: Cash and cash equivalents of $15.7 million. Total stockholders’ equity of $19.7 million. Total revenues of $658,998, a 30% increase over total revenues of $506,985 for the first quarter of last fiscal year. Net loss of $1,687,405. Net cash used in operating activities of $1,378,264.
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems.
Zoll Medical Corporation (NASDAQ:ZOLL), a manufacturer of medical devices and related software solutions, announced it will report its first quarter results following the close of the market on January 19, 2012. The Company will hold a conference call on that date at 5:00 p.m. Eastern Time (EST) to discuss its quarterly results, business highlights and outlook. This call will be webcast by Thomson Reuters and can be accessed at ZOLL’s web site at www.zoll.com.
ZOLL Medical Corporation develops, manufactures, and markets resuscitation devices, related data management and software solutions, and temperature management technology worldwide.
Vical Incorporated (Nasdaq:VICL) announced the online publication of a new article1 in The Lancet Infectious Diseases detailing results from the company’s completed Phase 2 proof-of-concept trial of its TransVax(TM) therapeutic vaccine, which is designed to control cytomegalovirus (CMV) infection or reactivation in transplant recipients. Separately, the company is participating this week in a two-day public workshop jointly sponsored by multiple agencies within the U.S. Department of Health and Human Services (HHS), “The Development and Evaluation of Human Cytomegalovirus Vaccines,” in connection with the company’s CyMVectin(TM) prophylactic vaccine, which is designed to elicit protective immunity in young women before they become pregnant, thereby protecting the fetus from transmission of CMV during pregnancy.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
No comments:
Post a Comment